Synthetic Methods in Drug Discovery
Volume 1
The number of available synthetic methods can be overwhelming. In order to create novel motifs and templates which confer new and potentially valuable drug-like properties, it is important to know which synthetic methodologies will give the best results. Similarly, which methodologies are used to progress potential drug candidates from leads through the development process? What are the current industrial research problems and how can they be resolved in an industrial setting? This book highlights key methods that have real impact in drug discovery and facilitate delivery of drug molecules.Synthetic Methods in Drug Discovery Volume 1 focuses…
Mehr
CHF 240.00
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
Weitere Autoren: Blakemore, David C (Hrsg.) / Doyle, Paul M (Hrsg.)
- ISBN: 978-1-78262-208-6
- EAN: 9781782622086
- Produktnummer: 35882246
- Verlag: Royal Society Of Chemistry
- Sprache: Englisch
- Erscheinungsjahr: 2016
- Seitenangabe: 455 S.
- Plattform: PDF
- Masse: 0 KB
Über den Autor
David Blakemore has spent his entire career in the pharmaceutical industry. Following his post-docs in Cambridge and Paris, he joined Warner-Lambert as a Group Leader in the Discovery Chemistry group. In 2001, he joined Pfizer in Sandwich and is currently the Synthesis Lead for the World-Wide Medicinal Chemistry Group at Pfizer Neusentis. Part of David's role is in liaising with academics to highlight key areas of chemistry that could be of real value to the pharmaceutical industry and to develop interactions in those areas.Paul Doyle has spent his entire career at the interface of chemistry and biology in the service of drug discovery. After his first degree in chemistry at Oxford, Paul completed his D.Phil. at the University of Sussex studying bio-organic synthetic chemistry. He spent a 15-year early career in a wide variety of therapeutic discovery programmes at the Wellcome Foundation before establishing one of the first UK discovery CROs, Biofocus. In 2008, Paul joined Peakdale as CEO.Yvette Fobian has spent the majority of her career in the pharmaceutical industry. After completing her PhD and spending a year in Monsanto's Corporate Research, she joined the Medicinal Chemistry Group in Searle/Monsanto in 1997 and ultimately Pfizer in 2003 following a series of mergers and acquisitions. In her most current role, Yvette is in an excellent position to see first-hand the needs and impact of synthetic enablement for both small and large scale delivery within the discovery team.
Bewertungen
Anmelden